GB 31650-2019 MRL × FDA ADE：泰乐菌素（Tylosin）
Cross-reference between China's veterinary-drug residue limit standard (GB 31650-2019, 食品中兽药最大残留限量) and the US FDA CVM adverse-event (ADE) report database (openFDA animalandveterinary/event.json). This is a structural link, not a clinical assertion.
MRL entry (GB 31650-2019, first-hand national standard text)
- 泰乐菌素（Tylosin） — 兽药分类: 大环内酯类抗生素
- MRL table: 表102（应符合表102的规定）
- Residue limits (靶组织 残留限量, μg/kg), verbatim from source:
- 脂肪100
- 肝100
- 肾100
- 奶100
- 蛋300
- *The drug name and each (tissue, value) pair are verbatim (whitespace-normalized) substrings of the landed GB 31650-2019 source text
pdf-raw/vet-drug-mrl/cn_gb31650.txt; the table reference above is likewise verbatim.*
OpenFDA ADE cross-reference
- OpenFDA ADE 报告数（tylosin）：2204（截至 2026-08-16，openFDA animalandveterinary/event.json 中以“tylosin”为活性成分检出的不良事件报告总数，报告级聚合）。
对应站内 FDA ADE topic：
- [tylosin → ade_tylosin_adverse_events](../../ade/ade_tylosin_adverse_events/01_tylosin.md)
Honest scope note
GB 31650-2019 is a food (residue-limit) standard, not a feed-additive standard — it governs residues in animal-derived *food* (meat, liver, kidney, fat, milk, egg). Its pet-food relevance is indirect: animal-origin pet-food ingredients (meat meal, poultry by-product, fish, egg, dairy) must comply. The ADE count reflects US spontaneous-reporting volume, not incidence or per-animal risk, and may not include China-specific products or trade names. Active-ingredient→OpenFDA term mapping is editorial; a 0 or low count may reflect openFDA ingredient naming rather than true absence of reports. Source: GB 31650-2019 source text cn_gb31650.txt + openFDA slice cn_gb31650_ade_2026-08-16.json (both pulled 2026-08-16).